Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from NeOnc Technologies Holdings, Inc. ( (NTHI) ) is now available.
On October 4, 2025, NeOnc Technologies Holdings, Inc. entered into a Master Services Agreement with Insights Pharmaceutical Research LLC to support its clinical development programs in the UAE. This agreement, which will transfer to NeOnc’s UAE subsidiary NuroCure, involves IROS conducting clinical trials, regulatory submissions, and data management, with the first project being a multi-site study on NEO100 for brain cancer. Additionally, NeOnc announced on October 9, 2025, its strategic expansion into the Middle East by signing the MSA with IROS and expanding its NuroMENA Board of Directors. This partnership with IROS, part of the M42 group, provides NeOnc with access to a world-class health ecosystem, accelerating the clinical development of its cancer therapies and positioning the company for operational excellence and strategic leadership in the region.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on developing and commercializing central nervous system therapeutics that address challenges in overcoming the blood-brain barrier. The company has developed a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038, including NEO100 and NEO212, which are in Phase II human clinical trials.
Average Trading Volume: 230,350
Technical Sentiment Signal: Strong Buy
For a thorough assessment of NTHI stock, go to TipRanks’ Stock Analysis page.